Faculty of Health and Medical Sciences, Dept of Respiratory Medicine, Child and Adolescent Health Service, University of Western Australia, Perth, Australia
Eur Respir Rev. 2018 Apr 5;27(147). doi: 10.1183/16000617.0133-2017. Print 2018 Mar 31.
Over the past year, studies into virus-induced wheeze in children have shifted towards investigations that examine the mechanisms by which respiratory viruses cause wheeze and an increase in studies examining the effects of novel interventions to reduce wheezing exacerbations. Studies on rhinovirus species (RV)-C infection have found that this is associated with a decrease in expression of CDHR3, the cellular receptor specific for this virus, and a decrease in interferon-β expression, both of which are likely to favour RV-C infection. Recent clinical trials in children have found a decrease in wheezing exacerbations with both anti-respiratory syncytial virus antibody and anti-immunoglobulin E antibody therapy, and a clinical trial of prednisolone in children with their first RV-induced wheeze showed that only those with an RV viral count >7000 copies·mL responded. Further studies on the effects of bacterial lysates on immune system function continue to support the potential of this approach to reduce virus-induced wheezing exacerbations in children. These studies and many previous investigations into immunomodulation using bacterial lysates have led to the funding and commencement of a large study in which long-term administration of a bacterial lysate in young children will be assessed for its ability to prevent asthma.
在过去的一年中,针对儿童病毒诱发喘息的研究已转向研究呼吸道病毒引起喘息的机制,并增加了研究新型干预措施以减少喘息加重的研究。关于鼻病毒(RV)-C 感染的研究发现,这与细胞受体 CDHR3 的表达减少有关,该病毒的细胞受体特异性降低,干扰素-β表达减少,这两者都可能有利于 RV-C 感染。最近在儿童中进行的临床试验发现,使用抗呼吸道合胞病毒抗体和抗免疫球蛋白 E 抗体治疗均可减少喘息加重,并且在儿童首次 RV 引起的喘息中进行的泼尼松龙临床试验表明,只有 RV 病毒载量>7000 拷贝·mL 的患者有反应。对细菌裂解物对免疫系统功能影响的进一步研究继续支持这种方法在减少儿童病毒诱发喘息加重方面的潜力。这些研究以及许多以前使用细菌裂解物进行免疫调节的研究导致了一项大型研究的资助和启动,该研究将评估在幼儿中长期使用细菌裂解物的能力,以预防哮喘。